Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Diseases and Conditions Researched

Idiopathic Pulmonary Fibrosis

What is the purpose of this trial?

This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: InterMune Pharmaceuticals, Inc.
Last Updated:
Study HIC#: 1406014085